Clinical Takeaway
Cannabis use for anxiety shows meaningful differences depending on whether someone uses flower or edible products, with daily and longer-term reductions in anxiety varying by product type and cannabinoid composition. CBD-containing products appear to offer anxiolytic benefits, while THC alone may not reliably reduce anxiety and could worsen it in some cases. Patients considering cannabis for anxiety management should discuss product type, cannabinoid ratios, and delivery method with their clinician before use.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study addresses a critical knowledge gap by characterizing how different cannabis product formulations affect anxiety outcomes in real-world use, moving beyond preclinical evidence to examine daily symptom patterns in patients self-selecting cannabis for therapeutic purposes. The differential effects between flower and edible products have important implications for product selection and dosing guidance, as route of administration and pharmacokinetics directly influence THC and CBD bioavailability and could meaningfully impact clinical efficacy and safety profiles. Understanding these longitudinal patterns is essential for establishing evidence-based recommendations for patients with anxiety disorders seeking cannabis as an adjunctive or alternative therapeutic option.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This longitudinal study provides useful real-world data on how different cannabis product types may differentially affect anxiety symptoms over time, addressing a significant gap since most anxiety research focuses on isolated cannabinoids rather than whole-plant products as patients actually use them. The finding that flower and edibles show distinct daily and longitudinal anxiety trajectories is clinically relevant, though we must note important limitations: the self-selected sample of individuals motivated to use cannabis for anxiety may not represent typical patients, the study lacks a control group, and without detailed THC:CBD ratios and dosing data, we cannot definitively attribute effects to specific cannabinoid profiles or product characteristics. Additionally, anxiety symptom measurement through daily self-report is prone to bias and regression to the mean, and the 30-day window may be insufficient to distinguish acute anxiety relief from placebo effects or natural symptom fluctuation. For practitioners counseling patients on cannabis for anxiety, these findings suggest that product format warrants discussion during shared decision-making, but current evidence remains insufficient to recommend cannabis